PMID- 8793912
OWN - NLM
STAT- MEDLINE
DCOM- 19961203
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 35
IP  - 4
DP  - 1996 Apr
TI  - 5-HT1A receptor antagonists and lordosis behavior.
PG  - 489-95
AB  - In proestrous rats, serotonin 1A (5-HT1A) receptor agonists inhibit lordosis 
      behavior within 5-15 min following infusion into the ventromedial nucleus of the 
      hypothalamus (VMN). In the present report, the lordosis-inhibiting effects of the 
      5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were 
      shown to be attenuated with 5-HT1A receptor antagonists. Two compounds, 
      propranolol and pindolol, that function as both beta-adrenergic and 5-HT1A 
      receptor antagonists, and (+) WAY100135 (chiral N-t-butyl-3-(1-(4-(2-methoxy) 
      phenyl)piperazinyl)-1-phenylpropionamide dihydrochloride, quarter hydrate), a 
      more selective 5-HT1A receptor antagonist, were found to reduce the 
      lordosis-inhibiting effects of 8-OH-DPAT infusion into the VMN. Proestrous rats 
      were co-infused into the VMN with 200 ng 8-OH-DPAT plus 1000 ng or 2000 ng 
      pindolol, 1000 ng or 2000 ng propranolol, or 2000 ng (+) WAY100135. Co-infusion 
      with 1000 ng or 2000 ng pindolol attenuated the inhibitory effects of 8-OH-DPAT; 
      co-infusion of 1000 ng, but not 2000 ng, propranolol, reduced the effects of 
      8-OH-DPAT; and co-infusion with 2000 ng (+) WAY100135 attenuated the effects of 
      8-OH-DPAT. Bilateral VMN infusion with 2500 ng (+) WAY100135 facilitated lordosis 
      behavior in suboptimally, hormone-primed ovariectomized rats. These findings 
      strengthen the argument that the inhibitory effect of 5-HT1A receptor agonists on 
      lordosis behavior is the result of their activation of VMN 5-HT1A receptors.
FAU - Uphouse, L
AU  - Uphouse L
AD  - Department of Biology, Texas Woman's University, Denton 76204, USA.
FAU - Andrade, M
AU  - Andrade M
FAU - Caldarola-Pastuszka, M
AU  - Caldarola-Pastuszka M
FAU - Jackson, A
AU  - Jackson A
LA  - eng
GR  - GM08256/GM/NIGMS NIH HHS/United States
GR  - R01 HD28419/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Piperazines)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 133025-23-7 (WAY 100135)
RN  - 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - BJ4HF6IU1D (Pindolol)
SB  - IM
MH  - 8-Hydroxy-2-(di-n-propylamino)tetralin/*pharmacology
MH  - Adrenergic beta-Antagonists/pharmacology
MH  - Animals
MH  - Female
MH  - Hypothalamus, Middle
MH  - Infusions, Parenteral
MH  - Ovariectomy
MH  - Ovary/physiology
MH  - Pindolol/pharmacology
MH  - Piperazines/pharmacology
MH  - *Posture
MH  - Propranolol/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin Antagonists/*pharmacology
MH  - Serotonin Receptor Agonists/*pharmacology
MH  - Sexual Behavior, Animal/*drug effects
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 0028390895001964 [pii]
AID - 10.1016/0028-3908(95)00196-4 [doi]
PST - ppublish
SO  - Neuropharmacology. 1996 Apr;35(4):489-95. doi: 10.1016/0028-3908(95)00196-4.